文献速递临床试验与 GCP真实世界研究与卫生经济

受害者改善包(VIP)减少老年常见犯罪受害者慢性抑郁或焦虑症状的临床与成本效果:随机对照试验研究方案

The clinical and cost-effectiveness of a Victim Improvement Package (VIP) for the reduction of chronic symptoms of depression or anxiety in older victims of common crime (the VIP trial): study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-04-16

本研究为随机对照试验方案,旨在评估认知行为疗法(CBT)导向的受害者改善包(VIP)对老年犯罪受害者抑郁和焦虑症状的临床与成本效果。研究对象为65岁及以上、报案后一个月内筛查阳性并在3个月再筛查仍阳性的犯罪受害者,随机接受VIP+常规治疗(TAU)或单独TAU。主要结局为犯罪后6个月时贝克抑郁量表II和贝克焦虑量表的复合测量,计划随机226人。

要点

  • VIP为10次每周1小时的个体CBT导向心理治疗,由心理健康慈善机构Mind的治疗师提供。
  • 主要结局为犯罪后6个月BDI-II和BAI复合测量,并随访至犯罪后9个月。
  • 计划随机226人(1:1),以90%把握度和5%显著性水平检测组间至少0.5的标准差差异。

核心结论

  • 该试验旨在提供VIP对老年犯罪受害者焦虑和/或抑郁症状的临床与成本效果证据,并展示跨机构整合工作模式。

研究设计与样本

  • 随机对照试验方案,比较CBT导向的VIP联合常规治疗(TAU)与单独TAU。
  • 计划随机226名65岁及以上、报案后一个月内筛查阳性且3个月再筛查仍阳性的犯罪受害者,比例1:1。
  • 筛查工具为患者健康问卷-2和广泛性焦虑障碍-2,由伦敦警察厅更安全邻里团队在犯罪后一个月内进行。

关键数值与推荐

  • 主要结局为犯罪后6个月时贝克抑郁量表II(BDI-II)和贝克焦虑量表(BAI)的复合测量,并在犯罪后9个月随访。
  • 次要结局包括EQ-5D和修改版客户服务接收清单。
  • 样本量226例以90%把握度和5%显著性水平检测组间至少0.5的标准差差异,并调整治疗师聚类和潜在脱落。
  • 将进行成本效果分析,纳入干预成本以比较治疗组间的总体医疗成本和Quality of Life Years。

临床怎么用

  • 若证实有效,VIP可作为一种CBT导向的心理干预用于老年犯罪受害者,并由心理健康慈善机构治疗师提供。
  • 试验结果可为政策制定者、委托方和临床医生回应老年犯罪受害者需求提供证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Older people are vulnerable to sustained high levels of psychosocial distress following a crime. A cognitive behavioural therapy (CBT)-informed psychological therapy, the Victim Improvement Package (VIP) may aid recovery. The VIP trial aims to test the clinical and cost-effectiveness of the VIP for alleviating depressive and anxiety symptoms in older victims of crime. METHODS/DESIGN: People aged 65 years or more who report being a victim of crime will be screened by Metropolitan Police Service Safer Neighbourhood Teams within a month of the crime for distress using the Patient Health Questionnaire-2 and the Generalised Anxiety Disorder-2. Those who screen positive will be signposted to their GP for assistance, and re-screened at 3 months. Participants who screen positive for depression and/or anxiety at re-screening are randomised to a CBT informed VIP added to treatment as usual (TAU) compared to TAU alone. The intervention consists of 10 individual 1-h sessions, delivered weekly by therapists from the mental health charity Mind. The primary outcome measure is the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI), used as a composite measure, assessed at 6 months after the crime (post therapy) with a 9-month post-crime follow-up. Secondary outcome measures include the EQ-5D, and a modified Client Service Receipt Inventory. A total of 226 participants will be randomised VIP:TAU with a ratio 1:1, in order to detect a standardised difference of at least 0.5 between groups, using a mixed-effects linear-regression model with 90% power and a 5% significance level (adjusting for therapist clustering and potential drop-out). A cost-effectiveness analysis will incorporate intervention costs to compare overall health care costs and quality of life years between treatment arms. An embedded study will examine the impact of past trauma and engagement in safety behaviours and distress on the main outcomes. DISCUSSION: This trial should provide data on the clinical and cost-effectiveness of a CBT-informed psychological therapy for older victims of crime with anxiety and/or depressive symptoms and should demonstrate a model of integrated cross-agency working. Our findings should provide evidence for policy-makers, commissioners and clinicians responding to the needs of older victims of crime. TRIAL REGISTRATION: International Standard Randomised Controlled Trials Number, ID: ISRCTN16929670. Registered on 3 August 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Serfaty M, Aspden T, Satchell J, et al. The clinical and cost-effectiveness of a Victim Improvement Package (VIP) for the reduction of chronic symptoms of depression or anxiety in older victims of common crime (the VIP trial): study protocol for a randomised controlled trial. Trials. 2020. PMID: 32299478. doi:10.1186/s13063-020-4211-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。